tiprankstipranks
Ceryvyn Therapeutics Limited (DE:UKJ2)
MUNICH:UKJ2
Germany Market
UKJ2
Ceryvyn Therapeutics Limited
RESEARCH TOOLSreports

Ceryvyn Therapeutics Limited (UKJ2) Ratios

0 Followers

Ceryvyn Therapeutics Limited Ratios

DE:UKJ2's free cash flow for Q4 2024 was AU$-1.49. For the 2024 fiscal year, DE:UKJ2's free cash flow was decreased by AU$ and operating cash flow was AU$-1.65K. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
 2.94 2.94 5.25 4.98 44.46
Quick Ratio
 2.94 2.94 5.25 4.98 44.46
Cash Ratio
 2.69 2.69 4.76 3.71 38.05
Solvency Ratio
 -0.83 -0.83 -1.35 -7.29 -14.58
Operating Cash Flow Ratio
 -2.51 -2.51 -6.37 -5.62 -14.76
Short-Term Operating Cash Flow Coverage
 0.00 0.00 0.00 0.00 0.00
Net Current Asset Value
AU$ -76.41MAU$ -76.41MAU$ -9.18MAU$ 69.57MAU$ 179.81M
Leverage Ratios
Debt-to-Assets Ratio
 0.75 0.75 <0.01 0.00 <0.01
Debt-to-Equity Ratio
 -1.87 -1.87 -0.03 0.00 <0.01
Debt-to-Capital Ratio
 2.15 2.15 -0.03 0.00 <0.01
Long-Term Debt-to-Capital Ratio
 2.15 2.15 0.00 0.00 0.00
Financial Leverage Ratio
 -2.49 -2.49 -16.85 1.25 1.02
Debt Service Coverage Ratio
 -6.27 -6.30 -10.72 0.00 0.00
Interest Coverage Ratio
 -6.34 -6.34 -11.16 0.00 0.00
Debt to Market Cap
 0.29 0.93 0.00 0.00 0.00
Interest Debt Per Share
 0.27 2.15 0.04 0.00 <0.01
Net Debt to EBITDA
 0.15 0.15 0.60 0.49 2.98
Profitability Margins
Gross Profit Margin
100.00%17.42%-55.42%-85.91%-521.85%
EBIT Margin
-159940.37%-159940.37%-124518.33%-79263.52%-54667.10%
EBITDA Margin
-159857.73%-160443.72%-138554.61%-106489.56%-57455.77%
Operating Profit Margin
-153885.37%-153885.37%-138647.99%-106575.99%-57815.66%
Pretax Profit Margin
-184215.67%-184215.67%-136936.62%-109300.18%-73285.73%
Net Profit Margin
-176665.73%-176665.73%-131469.80%-102353.69%-66087.58%
Continuous Operations Profit Margin
-176665.73%-176665.73%-131469.80%-102353.69%-66087.58%
Net Income Per EBT
95.90%95.90%96.01%93.64%90.18%
EBT Per EBIT
119.71%119.71%98.77%102.56%126.76%
Return on Assets (ROA)
-116.66%-116.66%-142.98%-146.57%-32.97%
Return on Equity (ROE)
520.65%290.52%2409.60%-183.45%-33.73%
Return on Capital Employed (ROCE)
-153.80%-153.80%-186.16%-190.90%-29.51%
Return on Invested Capital (ROIC)
-147.39%-147.39%-178.58%-178.77%-26.59%
Return on Tangible Assets
-116.66%-116.66%-142.98%-146.57%-32.97%
Earnings Yield
-87.73%-145.30%-128.92%-43.58%-18.02%
Efficiency Ratios
Receivables Turnover
 0.01 0.01 0.02 0.00 0.00
Payables Turnover
 0.00 <0.01 0.01 0.02 0.24
Inventory Turnover
 0.00 0.00 250.47K 0.00 571.98K
Fixed Asset Turnover
 0.94 0.94 0.53 3.06 0.59
Asset Turnover
 <0.01 <0.01 <0.01 <0.01 <0.01
Working Capital Turnover Ratio
 <0.01 <0.01 <0.01 <0.01 <0.01
Cash Conversion Cycle
 34.62K -100.32K -11.14K -17.90K -1.54K
Days of Sales Outstanding
 34.62K 34.62K 14.86K 0.00 0.00
Days of Inventory Outstanding
 0.00 0.00 <0.01 0.00 <0.01
Days of Payables Outstanding
 0.00 134.94K 26.00K 17.90K 1.54K
Operating Cycle
 34.62K 34.62K 14.86K 0.00 <0.01
Cash Flow Ratios
Operating Cash Flow Per Share
 -0.25 -2.02 -0.38 -0.26 -0.18
Free Cash Flow Per Share
 -0.25 -2.02 -0.38 -0.26 -0.18
CapEx Per Share
 <0.01 <0.01 <0.01 <0.01 <0.01
Free Cash Flow to Operating Cash Flow
 1.00 1.00 1.00 1.00 1.00
Dividend Paid and CapEx Coverage Ratio
 -4.81K -4.81K -5.49K -4.22K -3.59K
Capital Expenditure Coverage Ratio
 -4.81K -4.81K -5.49K -4.22K -3.59K
Operating Cash Flow Coverage Ratio
 -1.14 -1.14 -656.83 0.00 -405.79
Operating Cash Flow to Sales Ratio
 -1.29K -1.29K -1.11K -786.64 -663.82
Free Cash Flow Yield
-32.96%-106.25%-13.64%-4.19%-2.26%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -1.14 -0.69 -0.78 -2.29 -5.55
Price-to-Sales (P/S) Ratio
 3.91K 1.22K 1.02K 2.35K 3.67K
Price-to-Book (P/B) Ratio
 -3.31 -2.00 -18.69 4.21 1.87
Price-to-Free Cash Flow (P/FCF) Ratio
 -3.03 -0.94 -0.92 -2.98 -5.52
Price-to-Operating Cash Flow Ratio
 -1.56 -0.94 -0.92 -2.99 -5.53
Price-to-Earnings Growth (PEG) Ratio
 0.07 >-0.01 -0.02 -0.03 -0.03
Price-to-Fair Value
 -3.31 -2.00 -18.69 4.21 1.87
Enterprise Value Multiple
 -2.29 -0.60 -0.14 -1.72 -3.41
Enterprise Value
 457.80M 120.75M 1.18B 2.28B 2.54B
EV to EBITDA
 -2.30 -0.60 -5.29 -17.16 -48.09
EV to Sales
 3.67K 968.58 7.33K 18.27K 27.63K
EV to Free Cash Flow
 -2.84 -0.75 -6.59 -23.22 -41.62
EV to Operating Cash Flow
 -2.84 -0.75 -6.59 -23.23 -41.63
Tangible Book Value Per Share
 -0.12 -0.95 -0.02 0.19 0.53
Shareholders’ Equity Per Share
 -0.12 -0.95 -0.02 0.19 0.53
Tax and Other Ratios
Effective Tax Rate
 0.04 0.04 0.04 0.06 0.10
Revenue Per Share
 <0.01 <0.01 <0.01 <0.01 <0.01
Net Income Per Share
 -0.35 -2.76 -0.45 -0.34 -0.18
Tax Burden
 0.96 0.96 0.96 0.94 0.90
Interest Burden
 1.15 1.15 1.10 1.38 1.34
Research & Development to Revenue
 1.41K 1.41K 1.13K 867.35 377.36
SG&A to Revenue
 124.24 124.24 119.57 130.39 129.14
Stock-Based Compensation to Revenue
 40.79 40.79 36.20 42.00 42.37
Income Quality
 0.73 0.73 0.85 0.77 1.00
Currency in AUD